Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.

Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA.

Schizophr Res. 2008 Apr;101(1-3):273-86. doi: 10.1016/j.schres.2007.12.487. Epub 2008 Feb 6.

2.

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA.

Schizophr Res. 2008 Aug;103(1-3):104-9. doi: 10.1016/j.schres.2008.04.023. Epub 2008 Jun 4.

4.

Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study.

Saddichha S, Manjunatha N, Ameen S, Akhtar S.

Schizophr Res. 2008 Apr;101(1-3):266-72. doi: 10.1016/j.schres.2008.01.004. Epub 2008 Feb 11. Erratum in: Schizophr Res. 2008 Sep;104(1-3):307-8.

PMID:
18262771
5.

Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.

Smith RC, Lindenmayer JP, Hu Q, Kelly E, Viviano TF, Cornwell J, Vaidhyanathaswamy S, Marcovina S, Davis JM.

Schizophr Res. 2010 Jul;120(1-3):204-9. doi: 10.1016/j.schres.2010.04.001. Epub 2010 May 10.

PMID:
20457512
6.

The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RS, Stroup TS, Lieberman JA.

Schizophr Res. 2005 Dec 1;80(1):9-18. Epub 2005 Aug 24.

PMID:
16125372
7.

Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.

Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J, Hu Q, Khan A, Vaidhyanathaswamy S.

J Clin Psychiatry. 2009 Nov;70(11):1501-13. doi: 10.4088/JCP.08m04446yel. Epub 2009 Oct 6.

PMID:
19814947
8.

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA.

Schizophr Res. 2005 Dec 1;80(1):19-32. Epub 2005 Aug 30.

PMID:
16137860
9.

The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study.

Chue P, Mandel FS, Therrien F.

Curr Med Res Opin. 2014 Jun;30(6):997-1005. doi: 10.1185/03007995.2014.898139. Epub 2014 Mar 17.

PMID:
24568177
12.

Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.

Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM.

JAMA Psychiatry. 2014 Dec 1;71(12):1350-63. doi: 10.1001/jamapsychiatry.2014.1314.

PMID:
25321337
13.

Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up.

Medved V, Kuzman MR, Jovanovic N, Grubisin J, Kuzman T.

J Psychopharmacol. 2009 Nov;23(8):915-22. doi: 10.1177/0269881108093927. Epub 2008 Jul 17.

PMID:
18635691
14.

The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.

Bonaccorso S, Sodhi M, Li J, Bobo WV, Chen Y, Tumuklu M, Theleritis C, Jayathilake K, Meltzer HY.

Bipolar Disord. 2015 Aug;17(5):528-35. doi: 10.1111/bdi.12294. Epub 2015 Apr 15.

PMID:
25874530
15.

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group.

Schizophr Res. 2007 Feb;90(1-3):162-73. Epub 2006 Nov 21.

PMID:
17123783
16.

Prevalence of metabolic syndrome among Filipino adults aged 20 years and over.

Tanchoco CC, Cruz AJ, Duante CA, Litonjua AD.

Asia Pac J Clin Nutr. 2003;12(3):271-6.

17.

Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.

Fleischhacker WW, Siu CO, Bodén R, Pappadopulos E, Karayal ON, Kahn RS; EUFEST study group.

Int J Neuropsychopharmacol. 2013 Jun;16(5):987-95. doi: 10.1017/S1461145712001241. Epub 2012 Dec 20.

PMID:
23253821
18.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
19.

Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.

Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B.

Schizophr Res. 2009 Feb;107(2-3):115-21. doi: 10.1016/j.schres.2008.09.028. Epub 2008 Nov 6.

PMID:
18993033
20.

The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.

Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, De Hert M.

Int Clin Psychopharmacol. 2011 Nov;26(6):291-302. doi: 10.1097/YIC.0b013e32834a5bf6.

PMID:
21876442

Supplemental Content

Support Center